Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BGE-175

Other · developed by BioAge Labs

Phase 2 Most advanced trial (none active)
BIOA Developer
1 Registered trials

What is BGE-175?

BGE-175 is a drug code name studied in COVID-19 and respiratory insufficiency.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Infectious disease, Respiratory
Developer
BioAge Labs, Inc. (BIOA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
B2LW71CRGL

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04705597 Phase 2 Covid19 Terminated BIOA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Covid19

More from BioAge Labs

Follow BIOA, the company behind BGE-175

See BIOA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BIOA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.